RapidAI announced that it received FDA 510(k) clearance for its Rapid RV/LV tool for detecting pulmonary embolism (PE) severity.
San Mateo, California-based RapidAI designed Rapid RV/LV to quickly assess the ratio between right ventricle and left ventricle. This RV/LV metric represents a key indicator of PE severity. Automating the process enables the care team to more quickly prioritize patients and accelerate decision-making.
Rapid RV/LV uses artificial intelligence (AI) to analyze computerized tomography pulmonary angiograms (CTPAs). It automatically calculates the RV/LV ratio within minutes. The system comprises part of the Rapid PE triage and notification product. With combined results, PE teams can make faster care decisions and communicate for truly coordinated care.
The platform offers quick identification of patients with possible right heart strain and reduces time to diagnosis. RapidAI said in a news release it reduces variability and standardizes RV/LV measurement.
“Rapid PE streamlines the care pathway from the moment a suspected PE patient is scanned, to diagnosis and through treatment – reducing the complexities that come with managing PE, helping teams triage patients faster, and reducing overall time to treatment,” said Karim Karti, CEO of RapidAI. “The FDA clearance of Rapid RV/LV further enhances our PE solution by providing physicians with an immediate view into patients suffering from RV strain, which is critical to getting the right patients to the right care as fast as possible.
“This is yet another step toward delivering AI-based solutions that help physicians further enhance patient care and impact patient outcomes to ultimately improve quality of life – something we are very proud to be part of.”
